Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Sanofi
Celgene
Alliance for Clinical Trials in Oncology
Amgen
University of Ulm
Teva Branded Pharmaceutical Products R&D, Inc.
University Hospital, Lille
University of Oklahoma
Ottawa Hospital Research Institute
Canadian Cancer Trials Group
Merck Sharp & Dohme LLC
Kangdong Sacred Heart Hospital
Ohio State University Comprehensive Cancer Center
OHSU Knight Cancer Institute
University of Kansas Medical Center
Emory University
China Medical University, China
M.D. Anderson Cancer Center
Jiangsu Simcere Pharmaceutical Co., Ltd.
University of Arkansas
Valerio Therapeutics
Sunnybrook Health Sciences Centre
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen-Cilag G.m.b.H
University of Kentucky
Ohio State University Comprehensive Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
University Health Network, Toronto